Important Safety Information | NIOX VERO® User Manual (PDF)

For US Healthcare Professionals Only

Distributors

When we say Gold Standard, we mean it.
Learn more about the unique technology behind NIOX®

The device of choice

Thousands of healthcare professionals are using NIOX VERO® every day to improve patient outcomes.

With over 40 million tests completed worldwide, NIOX® is dedicated to transforming asthma care.

Discover why NIOX VERO® is the ultimate FeNO solution.

All that in 2 minutes!

From inhaling to analysis, you only need one test to reveal an accurate and reliable FeNO result for your patients, at the point-of-care.

Set up for success

Once you start testing with NIOX VERO®, you never have to stop. The device does not need any servicing, maintenance or calibration. Ever.

Why?
Our sensors are individually calibrated and tested against nitric oxide reference gas for guaranteed accuracy.

All NIOX® devices and consumables have been tested and validated in accelerated aging studies and real-time stability data, demonstrating that NIOX® products are robust, reliable and accurate over their lifetime.

There's more to NIOX®

With NIOX® Apps, our unique software applications, you can sync your NIOX® data into an easy-to-use management system.

Create patient reports, track their progress and share data with your own database.

Get started with NIOX VERO®

Join the thousands of healthcare professionals who have already performed over 40 million FeNO tests with NIOX®, and improve patient outcomes.

References

1. Menzies-Gow A et al. Clinical utility of fractional exhaled nitric oxide in severe asthma management. Eur Respir J. 2020;55(3):1901633. 2. Dweik RA et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FeNO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602-15. 3. Data on file C-NIOX-0001. Circassia Ltd. 4. Data on file C-NIOX-0004. Circassia Ltd. 5. Alving K et al. Validation of a new portable exhaled nitric oxide analyzer, NIOX VERO®: randomized studies in asthma. Pulm Ther. 2017;3:207-218. 6. Data on file C-NIOX-0010. Circassia Ltd. 7. Data on file C-NIOX-0009. Circassia Ltd. 8. Jackson T et al. Classification of aerosol-generating procedures: a rapid systematic review. BMJ Open Respir Res. 2020;7(1):e000730. 9. Global Asthma Network. The Global Asthma Report. 2018. 10. Hanania NA et al. Measurement of fractional exhaled nitric oxide in real-world clinical practice alters asthma treatment decisions. Ann Allergy Asthma Immunol. 2018;120(4):414-418. 11. Wang K et al. Using fractional exhaled nitric oxide to guide step-down treatment decisions in patients with asthma: a systematic review and individual patient data meta-analysis. Eur Respir J. 2020;55(5):1902150. 12. Heaney LG et al. Medical Research Council UK Refractory Asthma Stratification Programme (RASP-UK). Remotely monitored therapy and nitric oxide suppression identifies nonadherence in severe asthma. Am J Respir Crit Care Med. 2019;199(4):454-464. 13. Syk J et al. Anti-inflammatory treatment of atopic asthma guided by exhaled nitric oxide: a randomized, controlled trial. J Allergy Clin Immunol Pract. 2013;1(6):639-48. 14. Peirsman EJ et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatr Pulmonol. 2014 Jul;49(7):624-31. 15. Mansur AH et al. Disconnect of type 2 biomarkers in severe asthma; dominated by FeNO as a predictor of exacerbations and periostin as predictor of reduced lung function. Respir Med. 2018;143:31-38.

ICS: Inhaled Corticosteroids